Want to see HK:1358 full AI Analyst Report?
1358 Stock Chart & Stats
HK$1.30
HK$0.02(2.06%)
At close: 4:00 PM EST
HK$1.30
HK$0.02(2.06%)
Day’s Range― - ―
52-Week RangeHK$0.97 - HK$1.63
Previous CloseN/A
Volume329.00K
Average Volume (3M)1.12M
Market Cap
HK$1.45B
Enterprise Value-HK$358.96M
Total Cash (Recent Filing)HK$1.81B
Total Debt (Recent Filing)HK$22.01M
Price to Earnings (P/E)13.8
Beta0.25
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.34%
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,433,241,100
10 Day Avg. Volume754,100
30 Day Avg. Volume1,124,400
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)0.44
Price to Sales (P/S)2.13
P/FCF Ratio12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage provides durable financial flexibility: it reduces interest and refinancing risk, supports capital allocation for R&D, dividends or M&A, and increases resilience through economic cycles. This structural strength underpins long-term stability and strategic optionality.
Positive Free Cash FlowSustained positive free cash flow means the business generates internal funding for operations, capex and shareholder returns without needing external financing. Even with recent weakening, persistent FCF supports durable dividend capacity and reinvestment over the medium term.
High Historical Gross MarginsConsistently high gross margins indicate strong product-level profitability and pricing/scale advantages in medical instruments. This structural margin base provides buffer against cost pressure and supports long-term operating leverage when revenue growth resumes.
Bears Say
Recent Revenue DeclineA top-line contraction signals weakening end-market demand or competitive displacement. Over a multi-month horizon this reduces operating leverage, limits scope for margin recovery, and can slow reinvestment rates, challenging the company’s medium-term growth trajectory.
Margin CompressionSubstantial year-over-year margin erosion materially reduces earnings power and free cash flow generation. If structural rather than cyclical, compressed margins weaken return on invested capital and limit ability to sustain dividends or fund growth without cutting costs or raising prices.
Inconsistent Cash Conversion & TransparencyVolatile FCF and missing cash-conversion metrics impair clarity on how profits translate to liquidity. This raises uncertainty about sustainable shareholder distributions and internal funding capacity, increasing the risk profile for multi-month planning and capital allocation decisions.
PW Medtech Group Ltd. News
1358 FAQ
What was PW Medtech Group Ltd.’s price range in the past 12 months?
PW Medtech Group Ltd. lowest stock price was HK$0.97 and its highest was HK$1.63 in the past 12 months.
What is PW Medtech Group Ltd.’s market cap?
PW Medtech Group Ltd.’s market cap is HK$1.45B.
When is PW Medtech Group Ltd.’s upcoming earnings report date?
PW Medtech Group Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 22 days.
How were PW Medtech Group Ltd.’s earnings last quarter?
PW Medtech Group Ltd. released its earnings results on Mar 27, 2026. The company reported HK$0.021 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.021.
Is PW Medtech Group Ltd. overvalued?
According to Wall Street analysts PW Medtech Group Ltd.’s price is currently Overvalued.
Does PW Medtech Group Ltd. pay dividends?
PW Medtech Group Ltd. pays a Semiannually dividend of HK$0.02 which represents an annual dividend yield of 6.34%. See more information on PW Medtech Group Ltd. dividends here
What is PW Medtech Group Ltd.’s EPS estimate?
PW Medtech Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PW Medtech Group Ltd. have?
PW Medtech Group Ltd. has 1,433,241,100 shares outstanding.
What happened to PW Medtech Group Ltd.’s price movement after its last earnings report?
PW Medtech Group Ltd. reported an EPS of HK$0.021 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.009%.
Which hedge fund is a major shareholder of PW Medtech Group Ltd.?
Currently, no hedge funds are holding shares in HK:1358
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PW Medtech Group Ltd.
Operating within the People's Republic of China, PW Medtech Group Limited is an investment holding company primarily engaged in the medical device industry. The company specializes in the manufacturing and distribution of a diverse portfolio of medical consumables, including various types of infusion sets such as non-PVC, precision filter, and light-resistant models, alongside intravenous cannula products and insulin needles and pens. Beyond its core medical device activities, the group also provides property management services. Established in 1997, the company, previously known as Pyholding Limited, maintains its corporate headquarters in Beijing, China.
Technical Analysis
Shandong Weigao Group Medical Polymer Co
―
Modern Dental Group Limited
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―
OrbusNeich Medical Group Holdings Limited
―